Quantcast J&j Buys Chinese Cosmetics Company For $300m
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

J&j Buys Chinese Cosmetics Company For $300m

Posted on 04/09/2007 18:54:20 | Link | Post Comment
by Richard Daverman, PhD
Centient Biotech Investor



Johnson & Johnson (JNJ) paid $300 million to buy Dabao Cosmetics Co., the largest cosmetics company in China. The purchase price represents a P/E multiple of 57. In 2006, Dabao produced $5.3 million in profit on revenue of $86.7 million. It has net assets of $59 million. J&J is also in the cosmetics business, as it produces the Neutrogena line of cosmetics.

Dubao, a state-owned company, put itself up for sale earlier this year. By requiring a bank guarantee for the full purchase price, Dabao cut some potential bidders out of running. Avon (AVN), in particular, was thought to be interested, because it was recently allowed to re-introduce its direct selling business model in China, and it lacks the kind of low-price products that are Dubao’s specialty. Dabao also stipulated that bidders have a global presence and registered capital of at least $2.5 billion.

Dabao emerged in 1999, built on the restructured state-owned Beijing cosmetic factory. According to newspaper reports, 41% of Dabao’s employees are handicapped, and J&J agreed to handle their employment “appropriately,” though the exact meaning of the phrase was not specified.

Dabao has over 3,000 outlets in China, many of them in second-tier cities. The acquisition will facilitate J&J’s foray into the Chinese market, which is expected to grow. The low and medium priced products from Dubao will round out the higher priced products from Neutrogena.

Some Chinese observers worry about the disappearance of familiar brands, following an acquisition. After Proctor & Gamble (PG) took over the washing powder Panda, for example, the familiar Chinese brand’s penetration of its home market dropped from more than 10% to almost nothing, as P&G substituted western products.


Source: CentientInvestor.com



RELATED READING:
- China Biotech Review: Cancer Therapeutics Sues Partner Peregrine
- Beijing Med-Pharm Extends Chinese Distribution Network
- Offshoring of Biotech Research to China

_____________________
Stock Quote or
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Tue Oct 07, 2008 10:07PM
Today we have the Fed speaking and release of Fed mi [read more]
Morpheus Trading - Tue Oct 07, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.